BCA
NVO

Bay Colony Advisors’s Novo Nordisk NVO Stock Holding History

Bay Colony Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,970
Closed -$276K – 527
2025
Q3 		$276K Sell
4,970
-9,003
-64% -$527K 0.03% 412
2025
Q2 		$964K Sell
13,973
-437
-3% -$29.7K 0.13% 148
2025
Q1 		$999K Buy
14,410
+3,656
+34% +$302K 0.15% 144
2024
Q4 		$925K Sell
10,754
-2,923
-21% -$316K 0.14% 152
2024
Q3 		$1.63M Sell
13,677
-2,261
-14% -$302K 0.25% 90
2024
Q2 		$2.27M Sell
15,938
-1,436
-8% -$190K 0.38% 54
2024
Q1 		$2.23M Buy
17,374
+6,778
+64% +$807K 0.39% 49
2023
Q4 		$1.1M Buy
10,596
+4,663
+79% +$461K 0.22% 103
2023
Q3 		$540K Buy
5,933
+1,689
+40% +$149K 0.13% 162
2023
Q2 		$343K Buy
4,244
+550
+15% +$44.9K 0.08% 214
2023
Q1 		$292K Buy
+3,694
New +$262K 0.08% 234

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bay Colony Advisors's NVO Position: Q4 2025 in Review

Bay Colony Advisors sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 4,970 shares — an estimated $276K sold.

Bay Colony Advisors first reported a position in NVO in Q1 2023 and held it in 11 quarters. The position peaked at $2.27M in Q2 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Bay Colony Advisors reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Bay Colony Advisors sold 4,970 Novo Nordisk shares in Q4 2025, an estimated $276K.
  • Bay Colony Advisors first reported a position in Novo Nordisk in Q1 2023 and held it in 11 quarters.
  • Bay Colony Advisors's Novo Nordisk position peaked at $2.27M in Q2 2024.
  • 1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Bay Colony Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.